Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Accelerated Approval Of Lilly’s Alzheimer’s Drug Could Last About 15 Months, CEO Says

Jul 15 2021

• By Brenda Sandburg

Alzheimer's research — Lilly expects to complete confirmatory trial to support accelerated approval of its Alzheimer's disease drug in 2023 • Source: Alamy

Related Content

3,189 Days: Aduhelm Phase IV Timeline Is Long Among Alzheimer’s Drugs And Other Accelerated Approvals

Jul 13 2021

Aduhelm Approval Firestorm Raises Question: What Are US FDA Advisory Committees For, Anyway?

Jun 11 2021

Medicare Coverage Analysis Of Alzheimer’s Drugs Begins With Focus On Outcomes, Patient Eligibility

Jul 14 2021

Woodcock Requests Independent Review Of Biogen-FDA Aduhelm Interaction … Not Approval Decision

Jul 10 2021

Lilly’s Donanemab Could Be A Near-Term Aduhelm Competitor

Jun 24 2021

Lilly’s New Anti-Amyloid Play Hinges On Tau Bet

Mar 16 2021

Related Companies

Eli Lilly and Company

Biogen, Inc.

Eisai Co., Ltd.

Additional Topics

United States Clinical Trials Drug Approval Standards Research & Development Regulation Leadership Neurology BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window